Artificial Blood Substitute Market Forecast 2026-2032: Rising Trauma Cases and Biotech Innovation Drive Next-Generation Oxygen Therapeutics Growth

LOS ANGELES, United States: The global Artificial Blood Substitute market report offers fine intelligence that prepares market players to compete well against their toughest competitors on the basis of growth, sales, and other vital factors. The research study lays emphasis on key growth opportunities and market trends apart from critical market dynamics including market drivers and challenges. With the help of this report, interested parties can equip themselves to adapt according to the changes in the Artificial Blood Substitute industry and secure a strong market position for years to come. The report provides market development statistics, a list of select leading players, deep regional analysis, and a broad market segmentation study to give a complete understanding of the global Artificial Blood Substitute market.

The global market for Artificial Blood Substitute was estimated to be worth US$ 14.17 million in 2025 and is projected to reach US$ 46.27 million, growing at a CAGR of 17.7% from 2026 to 2032.

The global key companies of Artificial Blood Substitute include Perftoran, HbO2 Therapeutics, Hemarina, Aurum Biosciences Ltd., KaloCyte Inc., Prolong Pharmaceuticals, NuvOx Pharma, etc. In 2025, the global two largest players hold a share approximately 92% in terms of revenue.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart): https://www.qyresearch.in/request-sample/pharma-healthcare-global-artificial-blood-substitute-market-insights-industry-share-sales-projections-and-demand-outlook-2026-2032

Market Key Drivers

The market for artificial blood substitutes is primarily driven by increasing medical demand and advancements in technology. On a global scale, the demand for blood transfusions continues to rise, while the availability of suitable blood is often constrained by challenges such as blood type compatibility, limited shelf life, and underdeveloped blood supply systems. Artificial blood substitutes can play a vital role in emergency care, mass casualty incidents, and battlefield medicine. In addition, the accelerating aging population, along with the growing number of major surgeries and trauma cases, has created strong clinical demand for safe, long-lasting, and universally compatible alternatives. Advances in bioengineering, nanotechnology, and synthetic biology are also fostering the development of more efficient and stable products. Furthermore, concerns over transfusion-related infections and low blood donation rates in certain regions are encouraging healthcare systems to prioritize artificial blood solutions, collectively driving market growth.

Regional Insights

Regional insights indicate that North America remains a leading region due to advanced healthcare infrastructure, active clinical research programs, and strong investment in biotechnology innovation. Europe is witnessing steady development supported by regulatory initiatives and research collaborations. Asia-Pacific is emerging as a promising growth region driven by expanding healthcare access and increasing clinical trial activity. In emerging economies, limited blood supply infrastructure is creating potential opportunities for alternative oxygen therapeutics. Regional regulatory frameworks and healthcare funding policies play a significant role in shaping market expansion.

Market Segmentation

Our market analysts are experts in deeply segmenting the global Artificial Blood Substitute market and thoroughly evaluating the growth potential of each and every segment studied in the report. Right at the beginning of the research study, the segments are compared on the basis of consumption and growth rate for a review period of nine years. The segmentation study included in the report offers a brilliant analysis of the global Artificial Blood Substitute market, taking into consideration the market potential of different segments studied. It assists market participants to focus on high-growth areas of the global Artificial Blood Substitute market and plan powerful business tactics to secure a position of strength in the industry.

Segment by Type

Perfluorocarbon-based Oxygen Carrier (PFBOC)
Hemoglobin-based Oxygen Carrier (HBOC)

Segment by Stage

Preclinical Stage
Clinical Trial Stage
Commercialization

Segment by Product Form

Solution-Based
Emulsion-Based
Others

Segment by Application

Military
Civil

Competitive Landscape

The report presents a detailed analysis of the competitive landscape along with company profiling of key players competing in the global Artificial Blood Substitute market. The authors of the report make it a point to provide readers with a complete evaluation of the vendor landscape and inform them about current and future changes therein. The competitive analysis offered in the report includes market share, gross margin, product portfolio, consumption, market status, and technologies of leading players operating in the global Artificial Blood Substitute market.

Key players profiled in the report on the Global Artificial Blood Substitute Market are:

Perftoran
HbO2 Therapeutics
Aurum Biosciences Ltd.
Hemarina
KaloCyte Inc.
Prolong Pharmaceuticals
NuvOx Pharma

How can the research study help your business?

(1) The information presented in the Artificial Blood Substitute report helps your decision makers to become prudent and make the best business choices.

(2) The report enables you to see the future of the global Artificial Blood Substitute market and accordingly take decisions that will be in the best interest of your business.

(3) It offers you a forward-looking perspective of the global Artificial Blood Substitute market drivers and how you can secure significant market gains in the near future.

(4) It provides SWOT analysis of the global Artificial Blood Substitute market along with useful graphics and detailed statistics providing quick information about the market's overall progress throughout the forecast period.

(5) It also assesses the changing competitive dynamics of the global Artificial Blood Substitute market using pin-point evaluation.

Request Pre-Order Enquiry or Customized Research On This Report: https://www.qyresearch.in/pre-order-inquiry/pharma-healthcare-global-artificial-blood-substitute-market-insights-industry-share-sales-projections-and-demand-outlook-2026-2032

Table of Content

1 Market Overview
1.1 Artificial Blood Substitute Product Introduction
1.2 Global Artificial Blood Substitute Market Size Forecast (2021-2032)
1.3 Artificial Blood Substitute Market Trends & Drivers
1.3.1 Artificial Blood Substitute Industry Trends
1.3.2 Artificial Blood Substitute Market Drivers & Opportunities
1.3.3 Artificial Blood Substitute Market Challenges
1.3.4 Artificial Blood Substitute Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Artificial Blood Substitute Players Revenue Ranking (2025)
2.2 Global Artificial Blood Substitute Revenue by Company (2021-2026)
2.3 Key Companies' R&D and Operations Footprint and Headquarters
2.4 Key Companies Artificial Blood Substitute Product Offerings
2.5 Key Companies General Availability (GA) Timeline for Artificial Blood Substitute
2.6 Artificial Blood Substitute Market Competitive Analysis
2.6.1 Artificial Blood Substitute Market Concentration Rate (2021-2026)
2.6.2 Top 5 and Top 10 Global Companies by Artificial Blood Substitute Revenue in 2025
2.6.3 Global Companies by Tier (Tier 1, Tier 2, Tier 3), based on Artificial Blood Substitute revenue, 2025
2.7 Mergers & Acquisitions and Expansion
3 Segmentation Artificial Blood Substitute Market Classification
3.1 Introduction by Type
3.1.1 Perfluorocarbon-based Oxygen Carrier (PFBOC)
3.1.2 Hemoglobin-based Oxygen Carrier (HBOC)
3.1.3 Global Artificial Blood Substitute Sales Value by Type
3.1.3.1 Global Artificial Blood Substitute Sales Value by Type (2021 vs 2025 vs 2032)
3.1.3.2 Global Artificial Blood Substitute Sales Value, by Type (2021-2032)
3.1.3.3 Global Artificial Blood Substitute Sales Value, by Type (%), 2021-2032
3.2 Introduction by Stage
3.2.1 Preclinical Stage
3.2.2 Clinical Trial Stage
3.2.3 Commercialization
3.2.4 Global Artificial Blood Substitute Sales Value by Stage
3.2.4.1 Global Artificial Blood Substitute Sales Value by Stage (2021 vs 2025 vs 2032)
3.2.4.2 Global Artificial Blood Substitute Sales Value, by Stage (2021-2032)
3.2.4.3 Global Artificial Blood Substitute Sales Value, by Stage (%), 2021-2032
3.3 Introduction by Product Form
3.3.1 Solution-Based
3.3.2 Emulsion-Based
3.3.3 Others
3.3.4 Global Artificial Blood Substitute Sales Value by Product Form
3.3.4.1 Global Artificial Blood Substitute Sales Value by Product Form (2021 vs 2025 vs 2032)
3.3.4.2 Global Artificial Blood Substitute Sales Value, by Product Form (2021-2032)
3.3.4.3 Global Artificial Blood Substitute Sales Value, by Product Form (%), 2021-2032
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Military
4.1.2 Civil
4.2 Global Artificial Blood Substitute Sales Value by Application
4.2.1 Global Artificial Blood Substitute Sales Value by Application (2021 vs 2025 vs 2032)
4.2.2 Global Artificial Blood Substitute Sales Value by Application (2021-2032)
4.2.3 Global Artificial Blood Substitute Sales Value by Application (%), 2021-2032
5 Segmentation by Region
5.1 Global Artificial Blood Substitute Sales Value by Region
5.1.1 Global Artificial Blood Substitute Sales Value by Region: 2021 vs 2025 vs 2032
5.1.2 Global Artificial Blood Substitute Sales Value by Region (2021-2026)
5.1.3 Global Artificial Blood Substitute Sales Value by Region (2027-2032)
5.1.4 Global Artificial Blood Substitute Sales Value by Region (%), 2021-2032
5.2 North America
5.2.1 North America Artificial Blood Substitute Sales Value, 2021-2032
5.2.2 North America Artificial Blood Substitute Sales Value by Country (%), 2025 vs 2032
5.3 Europe
5.3.1 Europe Artificial Blood Substitute Sales Value, 2021-2032
5.3.2 Europe Artificial Blood Substitute Sales Value by Country (%), 2025 vs 2032
5.4 Asia Pacific
5.4.1 Asia Pacific Artificial Blood Substitute Sales Value, 2021-2032
5.4.2 Asia Pacific Artificial Blood Substitute Sales Value by Subregion (%), 2025 vs 2032
5.5 South America
5.5.1 South America Artificial Blood Substitute Sales Value, 2021-2032
5.5.2 South America Artificial Blood Substitute Sales Value by Country (%), 2025 vs 2032
5.6 Middle East & Africa
5.6.1 Middle East & Africa Artificial Blood Substitute Sales Value, 2021-2032
5.6.2 Middle East & Africa Artificial Blood Substitute Sales Value by Country (%), 2025 vs 2032
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Artificial Blood Substitute Sales Value Growth Trends, 2021 vs 2025 vs 2032
6.2 Key Countries/Regions Artificial Blood Substitute Sales Value, 2021-2032
6.3 United States
6.3.1 United States Artificial Blood Substitute Sales Value, 2021-2032
6.3.2 United States Artificial Blood Substitute Sales Value by Type (%), 2025 vs 2032
6.3.3 United States Artificial Blood Substitute Sales Value by Application, 2025 vs 2032
6.4 Europe
6.4.1 Europe Artificial Blood Substitute Sales Value, 2021-2032
6.4.2 Europe Artificial Blood Substitute Sales Value by Type (%), 2025 vs 2032
6.4.3 Europe Artificial Blood Substitute Sales Value by Application, 2025 vs 2032
6.5 China
6.5.1 China Artificial Blood Substitute Sales Value, 2021-2032
6.5.2 China Artificial Blood Substitute Sales Value by Type (%), 2025 vs 2032
6.5.3 China Artificial Blood Substitute Sales Value by Application, 2025 vs 2032
6.6 Japan
6.6.1 Japan Artificial Blood Substitute Sales Value, 2021-2032
6.6.2 Japan Artificial Blood Substitute Sales Value by Type (%), 2025 vs 2032
6.6.3 Japan Artificial Blood Substitute Sales Value by Application, 2025 vs 2032
6.7 South Korea
6.7.1 South Korea Artificial Blood Substitute Sales Value, 2021-2032
6.7.2 South Korea Artificial Blood Substitute Sales Value by Type (%), 2025 vs 2032
6.7.3 South Korea Artificial Blood Substitute Sales Value by Application, 2025 vs 2032
6.8 Southeast Asia
6.8.1 Southeast Asia Artificial Blood Substitute Sales Value, 2021-2032
6.8.2 Southeast Asia Artificial Blood Substitute Sales Value by Type (%), 2025 vs 2032
6.8.3 Southeast Asia Artificial Blood Substitute Sales Value by Application, 2025 vs 2032
6.9 India
6.9.1 India Artificial Blood Substitute Sales Value, 2021-2032
6.9.2 India Artificial Blood Substitute Sales Value by Type (%), 2025 vs 2032
6.9.3 India Artificial Blood Substitute Sales Value by Application, 2025 vs 2032
7 Company Profiles
7.1 Perftoran
7.1.1 Perftoran Profile
7.1.2 Perftoran Main Business
7.1.3 Perftoran Artificial Blood Substitute Products, Services, and Solutions
7.1.4 Perftoran Artificial Blood Substitute Revenue (US$ Million), 2021-2026
7.1.5 Perftoran Recent Developments
7.2 HbO2 Therapeutics
7.2.1 HbO2 Therapeutics Profile
7.2.2 HbO2 Therapeutics Main Business
7.2.3 HbO2 Therapeutics Artificial Blood Substitute Products, Services, and Solutions
7.2.4 HbO2 Therapeutics Artificial Blood Substitute Revenue (US$ Million), 2021-2026
7.2.5 HbO2 Therapeutics Recent Developments
7.3 Aurum Biosciences Ltd.
7.3.1 Aurum Biosciences Ltd. Profile
7.3.2 Aurum Biosciences Ltd. Main Business
7.3.3 Aurum Biosciences Ltd. Artificial Blood Substitute Products, Services, and Solutions
7.3.4 Aurum Biosciences Ltd. Artificial Blood Substitute Revenue (US$ Million), 2021-2026
7.3.5 Aurum Biosciences Ltd. Recent Developments
7.4 Hemarina
7.4.1 Hemarina Profile
7.4.2 Hemarina Main Business
7.4.3 Hemarina Artificial Blood Substitute Products, Services, and Solutions
7.4.4 Hemarina Artificial Blood Substitute Revenue (US$ Million), 2021-2026
7.4.5 Hemarina Recent Developments
7.5 KaloCyte Inc.
7.5.1 KaloCyte Inc. Profile
7.5.2 KaloCyte Inc. Main Business
7.5.3 KaloCyte Inc. Artificial Blood Substitute Products, Services, and Solutions
7.5.4 KaloCyte Inc. Artificial Blood Substitute Revenue (US$ Million), 2021-2026
7.5.5 KaloCyte Inc. Recent Developments
7.6 Prolong Pharmaceuticals
7.6.1 Prolong Pharmaceuticals Profile
7.6.2 Prolong Pharmaceuticals Main Business
7.6.3 Prolong Pharmaceuticals Artificial Blood Substitute Products, Services, and Solutions
7.6.4 Prolong Pharmaceuticals Artificial Blood Substitute Revenue (US$ Million), 2021-2026
7.6.5 Prolong Pharmaceuticals Recent Developments
7.7 NuvOx Pharma
7.7.1 NuvOx Pharma Profile
7.7.2 NuvOx Pharma Main Business
7.7.3 NuvOx Pharma Artificial Blood Substitute Products, Services, and Solutions
7.7.4 NuvOx Pharma Artificial Blood Substitute Revenue (US$ Million), 2021-2026
7.7.5 NuvOx Pharma Recent Developments
8 Industry Chain Analysis
8.1 Artificial Blood Substitute Value Chain
8.2 Artificial Blood Substitute Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Key Suppliers of Raw Materials
8.2.3 Cost Structure
8.3 Midstream Analysis
8.4 Downstream (Customer) Analysis
8.5 Sales Model and Sales Channelss
8.5.1 Artificial Blood Substitute Sales Model
8.5.2 Sales Channels
8.5.3 Artificial Blood Substitute Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 18 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

Contact US

QY Research, INC.
17890 Castleton Street Suite 369
City of Industry, CA, 91748
United States
Email: ankit@qyresearch.com | Tel: +1 626 295 2442
Website: https://www.qyresearch.com

This release was published on openPR.